Are the guidelines correct? Should all patients with coronary heart disease or diabetes be treated with a statin?;Brauchen alle patienten mit KHK bzw. Diabetes ein statin?

Medizinische Klinik

Volumn 104, Issue 1, 2009, Pages 74-78

  Pöss, Janine ^a   Böhm, Michael ^b   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

End stage renal disease; GISSI HF; Ischemic heart failure; Statins; Withdrawal

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW;

AGED; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58749087905     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-009-1009-7     Document Type: Review

References (32)

1. ÄZfQid Medizin. Nationale Versorgungs Leitlinie "Chronische KHK". Berlin: ÄZfQid, 2006 (http:// www.versorgungsleitlinien. de).
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 2004;364:685-96.
4. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006;37:2640-3.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Fathi R, Isbel N, Short L, et al. The effect of long term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 2004;43:45-52.
7. Gohlke H, Kubler W, Mathes P, et al. [Position paper on the primary prevention of cardiovascular diseases. Current position of the 25.3.2003 statement of the board of the German Society of Cardiology - heart and circulatory research work commissioned by for the board by Project Group on Prevention.] Z Kardiol 2005;94:Suppl 3:III/113-5.
8. Graham I, Atar D, Borch Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14:Suppl 2:S1-113.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720-32.
10. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
11. Investigators GISSI HF. Effect of rosuvastatin in patients with chronic heart failure (the GISSI HF trial): a randomised, double blind, placebo controlled trial. Lancet 2008:in press (Epub 2008 Aug 29).
12. Jain MK, Ridker PM. Anti inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
13. Khush KK, Waters DD, Bittner V, et al. Effect of high dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576-83.
14. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
15. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a post hoc analysis of 5010 patients enrolled in Val HeFT. Int J Cardiol 2007;119:48-53.
16. Laufs U, Böhm M. Cardiac effects of statins - advancements and open questions. Cardiovasc Res 2005;66:427-9.
17. Laufs U, Custodis F, Böhm M. HMG CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 2006;66: 145-54.
18. Leite Moreira AF, Castro Chaves P. Heart failure: statins for all? Heart 2006;92:1537-8.
19. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin 2008;4:201-8.
20. McElduff P, Jaefarnezhad M, Durrington PN. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart 2006;92:1213-8.
21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008;359:2195-207.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
23. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102: 1893-900.
24. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT TIMI 22 study. J Am Coll Cardiol 2006;47:2326-31.
25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
26. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT LLA). Diabetes Care 2005;28:1151-7.
27. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-9.
28. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non ST segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 2004;164:2162-8.
29. Stegmayr BG, Brannstrom M, Bucht S, et al. Low dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol 2005;39:489-97.
30. Stossel TP. The discovery of statins. Cell 2008; 134:903-5.
31. Van der Harst P, Böhm M, van Gilst WH, et al. The case for statin therapy in chronic heart failure. Clin Res Cardiol 2008;97:139-46.
32. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.